Literature DB >> 15698446

Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration.

Bernard Lacour1, Anthony Lucas, Daniel Auchère, Nadya Ruellan, Natalie Mariaud de Serre Patey, Tilman B Drüeke.   

Abstract

BACKGROUND: Lanthanum (La) carbonate has recently been proposed as an alternative, calcium- and aluminum-free phosphate binder for the treatment of hyperphosphatemia of chronic renal failure (CRF). However, the extent to which CRF enhances tissue La accumulation induced by oral La overload above that observed under conditions of normal renal function remains a matter of debate. In the present study, we examined this issue in two different rat models of CRF.
METHODS: In a first series of experiments, adult male Sprague-Dawley rats received either a diet to which 0.3% adenine (wt% in feed) was added to induce CRF ("chemical CRF,"N= 20), or a diet free of adenine (control, N= 16). In a second series of experiments, adult male Sprague-Dawley rats underwent 5/6 nephrectomy in a two-step procedure ("surgical CRF,"N= 24). Half of all CRF and control rats were exposed to dietary La (3% lanthanum carbonate, wt% in feed) for four weeks (La[+] rats), whereas the other half received a placebo (La[-] rats).
RESULTS: At the end of this time period, creatinine clearance was 1.51 +/- 0.15 (mean +/- SEM) and 1.45 +/- 0.11 mL/min in La[-] control and La[+] control rats, and declined to 0.22 +/- 0.03 and 0.31 +/- 0.03 mL/min in La[+]-adenine-CRF and La[+]-Nx-CRF rats, respectively. Urinary La excretion was 0.025 +/- 0.010 microg/24 hr in La[-] control rats. It increased to 4.9 +/- 1.2, 17 +/- 3.8, and 77 +/- 18 microg/24 hr in La[+] control, La[+]-adenine-CRF, and La[+]-Nx-CRF rats, respectively. However, only the last value was significantly different from control value. Tissue La concentration was increased in La[+] control rats compared with La[-] control rats. More importantly, tissue La concentration was strikingly higher in La[+]-CRF rats than in La[+] control rats. Thus, liver La (ng/g dry wt) was 1173 +/- 148 in La[+]-adenine-CRF and 1742 +/- 158 in La[+]-Nx-CRF rats, respectively, compared with 385 +/- 29 in La[+] control rats (P < 0.001), and 7.0 +/- 1.4 in La[-] control rats; similarly, bone La was 230 +/- 14 and 288 +/- 26 compared with 81 +/- 8, respectively (P < 0.001), versus 27 +/- 4 in La[-] control rats. Comparable differences were observed in the kidney, skeletal muscle, myocardium, lung, and brain, although to different extents in La[+]-adenine-CRF compared with La[+]-Nx-CRF rats. Finally, liver and kidney weight was significantly reduced in La[+]-adenine-CRF rats compared with La[-]-adenine-CRF rats.
CONCLUSION: The oral administration of lanthanum carbonate to normal rats leads to a more than 10-fold increase of tissue La content in at least some organs, including the liver, lung, and kidney. This increase is further enhanced by the uremic state, per se. Plasma levels are a poor indicator of tissue burden. Given the dramatic tissue levels obtained with this rare earth metal given by the oral route, particularly in liver for absolute values, it is probable that the stimulation by CRF is at least partially explained by an increase in intestinal La absorption. The absorptive pathways involved in intestinal La absorption require further study, including possibly enhancing conditions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15698446     DOI: 10.1111/j.1523-1755.2005.00171.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  31 in total

1.  Treatment options of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease stages 3 and 4: an historic review.

Authors:  Piergiorgio Bolasco
Journal:  Clin Cases Miner Bone Metab       Date:  2009-09

2.  Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial.

Authors:  Darbie Maccubbin; Diane Tipping; Olga Kuznetsova; William A Hanlon; Andrew G Bostom
Journal:  Clin J Am Soc Nephrol       Date:  2010-03-18       Impact factor: 8.237

Review 3.  Vascular calcification in chronic kidney disease: Pathogenesis and clinical implication.

Authors:  Sinee Disthabanchong
Journal:  World J Nephrol       Date:  2012-04-06

4.  Protection of Chinese herbs against adenine-induced chronic renal failure in rats.

Authors:  Yanqing Tong; Bing Han; Hongyang Guo; Yanru Liu
Journal:  Afr J Tradit Complement Altern Med       Date:  2010-07-03

5.  Npt2b deletion attenuates hyperphosphatemia associated with CKD.

Authors:  Susan C Schiavi; Wen Tang; Christina Bracken; Stephen P O'Brien; Wenping Song; Joseph Boulanger; Susan Ryan; Lucy Phillips; Shiguang Liu; Cynthia Arbeeny; Steven Ledbetter; Yves Sabbagh
Journal:  J Am Soc Nephrol       Date:  2012-08-02       Impact factor: 10.121

6.  Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment.

Authors:  Alastair J Hutchison; M Edwina Barnett; Rolfdieter Krause; Jonathan T C Kwan; Ghodrat A Siami
Journal:  Nephron Clin Pract       Date:  2008-07-31

7.  Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial.

Authors:  Stuart M Sprague; Hanna Abboud; Ping Qiu; Matthew Dauphin; Pinggao Zhang; William Finn
Journal:  Clin J Am Soc Nephrol       Date:  2008-12-03       Impact factor: 8.237

8.  Gadolinium-containing bioparticles as an active entity to promote cell cycle progression in mouse embryo fibroblast NIH3T3 cells.

Authors:  Jin-Xia Li; Jing-Cheng Liu; Kui Wang; Xiao-Gai Yang
Journal:  J Biol Inorg Chem       Date:  2010-01-14       Impact factor: 3.358

9.  A confusional state associated with use of lanthanum carbonate in a dialysis patient: a case report.

Authors:  Michael D L Smyth; Raymond D Pratt
Journal:  Nephrol Dial Transplant       Date:  2009-09-27       Impact factor: 5.992

10.  Lanthanum associated abnormal liver function tests in two patients on dialysis: a case report.

Authors:  Girish Namagondlu; Norman Main; Lucy Yates; Joanne Mooney; Sangita Sathyamurthy; Indiver Daryanani; Alex Crowe; Tom Ledson; Anindya Banerjee
Journal:  J Med Case Rep       Date:  2009-12-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.